Single-cell profiling of PBMCs reveals distinct immune signatures associated with methotrexate response in rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease with complex pathogenesis and clinical heterogeneity. Methotrexate (MTX) is the cornerstone treatment for RA, yet 30–40% of patients exhibit an inadequate response. This study aims to systematically compare the differences in immune characteristics between treatment-naïve patients and those treated with MTX, as well as between MTX responders and non-responders to identify biomarkers of MTX response. We conducted single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs) from treatment-naïve (TN), treatment success (TS), and treatment failure (TF) RA patients. We focused on the impact of methotrexate treatment on the proportion of immune cells and explored the differences between the MTX response group and non-response group. The scRNA-seq data revealed that MTX can broadly attenuate lymphocyte proliferation and rebalanced proinflammatory T helper subsets. For MTX responders and non-responders, the TS group displayed enhanced type I interferon (IFN-I) signaling and elevated proportions of regulatory T cells (Tregs), whereas the TF group demonstrated activation of TNFα pathways and expansion of cytotoxic NK-CD56dim-CD16hi-IFNG, which could recruit classical monocytes. Our study unveils distinct immune mechanisms underlying MTX response and identifies FKBP5 as a potential prognostic biomarker for personalized RA therapy. Our research findings indicate that MTX plays a key role in rebalancing the proportion of immune cells, including reducing the proportion of proinflammatory Th1/Th17 cells, conventional dendritic cells (cDCs) and plasma cells and increasing the proportion of Th2 cells and Tregs. Additionally, we found that compared with the TS group, the TF group had a stronger TNFα response score in myeloid cells, whereas myeloid cells in the TS group exhibited a higher type I interferon (IFN-I) response score.
Authors
- Fan Bai (ORCID: https://orcid.org/0000-0001-6119-8936)
- Linmang Qin (ORCID: https://orcid.org/0000-0001-9859-8503)
- Lei Pei (ORCID: https://orcid.org/0000-0002-7557-5322)
- Qian Wang (ORCID: https://orcid.org/0000-0002-4541-9898)
- Shangyi Jin
- Yafang Deng
- Xinping Tian
Institutions
- Peking University (CN)
- Peking Union Medical College Hospital (CN)
- Center for Life Sciences (CN)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1186/s13075-026-03948-x
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Key Research and Development Program of China